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Abstract The insulin-producing b cells of pancreatic
islets are coupled by connexin36 (Cx36) channels. To
investigate what controls the expression of this connexin,
we have investigated its pattern during mouse pancreas
development, and the influence of three transcription fac-
tors that are critical for b-cell development and differen-
tiation. We show that (1) the Cx36 gene (Gjd2) is activated
early in pancreas development and is markedly induced at
the time of the surge of the transcription factors that
determine b-cell differentiation; (2) the cognate protein is
detected about a week later and is selectively expressed by
b cells throughout the prenatal development of mouse
pancreas; (3) a 2-kbp fragment of the Gjd2 promoter,
which contains three E boxes for the binding of the bHLH
factor Beta2/NeuroD1, ensures the expression of Cx36
by b cells; and (4) Beta2/NeuroD1 binds to these E boxes
and, in the presence of the E47 ubiquitous cofactor,
transactivates the Gjd2 promoter. The data identify Cx36
as a novel early marker of b cells and as a target of Beta2/
NeuroD1, which is essential for b-cell development and
differentiation.
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The insulin-producing b cells of pancreatic islets are cou-
pled by Cx36 channels (Serre-Beinier et al. 2000; Theis
et al. 2004). Although a previous report has documented
how this connexin is repressed in most cell types (Martin
et al. 2003), the mechanism that accounts for the consistent
expression of Cx36 in b cells, neurons and neuron-derived
cells (Bosco et al. 2011; Potolicchio et al. 2012) has not yet
been investigated. In view of the changes in Cx36 distri-
bution and levels which take place in different areas of the
developing brain, and which correlate with critical differ-
entiation steps of neuronal networks (Cina et al. 2007;
Gulisano et al. 2000), we hypothesized that important
insights about the obligatory expression of Cx36 in b cells
could be gained by establishing the expression profile of
the protein, as a function of the initiation, differentiation
and growth of b cells (Herrera 2000), as well as the sub-
sequent morphogenesis of pancreatic islets (Kim and
MacDonald 2002). Therefore, we have studied the tem-
poral and spatial expression of Cx36 during the pre- and
postnatal development of the mouse pancreas. To this end,
we used real-time PCR to evaluate the transcription of the
Cx36 gene (Gjd2), and immunofluorescence to investigate
the expression of the cognate protein during the develop-
ment of mouse pancreas.
In view of the tight correlation between the expression
of Gjd2 and the two insulin genes (Carvalho et al. 2010;
Serre-Beinier et al. 2009), we also hypothesized that the
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expression of Cx36 may be controlled by the same set of
transcription factors that regulate b-cell differentiation and
function (Kim and MacDonald 2002; Habener et al. 2005;
Murtaugh 2007; Jonsson et al. 1994; Naya et al. 1997;
Zhang et al. 2005). Given the restricted distribution of
Cx36 (Bosco et al. 2011; Potolicchio et al. 2012), we fur-
ther posited that the expression of Cx36 was likely to be
controlled by transcription factor or factors involved in the
differentiation and function of both pancreatic b cells
(Zhang et al. 2005) and neurons (Cho and Tsai 2004).
Therefore, we investigated the effects on Cx36 expression
of several transcription factors involved in pancreatic
development (Herrera 2000; Kim and MacDonald 2002;
Habener et al. 2005). To this end, we used a luciferase
reporter system to test different regions of the Gjd2 pro-
moter, chromatin immunoprecipitation assays to evaluate
the binding of Beta2/NeuroD1 to this promoter, and cell
transfections, as well as site-directed mutagenesis, to assess
the effects of Beta2/NeuroD1 on Cx36 expression. The
data show that Gjd2 is (1) expressed early in the devel-
opment of the mouse pancreas, as reported in the chicken
(Berthoud et al. 2004), and in a recent report (Pe´rez-
Armendariz et al. 2012) published since the submission of
this study; (2) encodes the cognate Cx36 protein at the time
of the second wave of b-cell differentiation; (3) is a hith-
erto nonidentified target of Beta2/NeuroD1, which controls
its expression by direct binding to the Gjd2 promoter.
Materials and Methods
Animals
Adult C57Bl/6 mice (Charles Rivers, Lyon, France) were
mated, and coupling confirmed by the presence of a vaginal
plug on the next morning (E0.5). Embryos were then
obtained from pregnant females at E11.5, E13.5, E15.5,
and E17.5. Control mice were also sacrificed at stages P0
and P2, and after 1–2 months of life.
Histology
Cryostat sections (5-lm thickness) of pancreas were fixed
for 10 min in 4 % paraformaldehyde (PFA) supplemented
with 0.1 % Triton X-100. Sections were then incubated
30 min in 0.1 M phosphate-buffered saline (PBS) supple-
mented with 2 % BSA, and exposed for 2 h at room tem-
perature to one of the following primary antibodies: rabbit
polyclonal antibody anti-Cx36 (Zymed 36-4600), diluted
1/50; guinea pig polyclonal antibody anti-insulin (Ventrex
Bioreagent 4043580), diluted 1/200; mouse monoclonal
antibody anti-glucagon (Sigma G2654), diluted 1/2000.
After rinsing, the sections were reacted with one of the
following secondary antibodies, whichever appropriate:
mouse anti-rabbit IgGs (Boehringer) conjugated to fluo-
rescein isothiocyanate, diluted 1/400; goat anti guinea pig
IgGs conjugated to rhodamine, diluted 1/200; goat anti-
mouse IgGs conjugated to rhodamine (Boehringer), diluted
1/200. Immunolabeling was visualized under UV
illumination.
RT-PCR
Total RNA was extracted from control mouse liver using
Trizol (Invitrogen), and from pancreas (E11.5-P0) using
the RNeasy micro kit (Qiagen), as recommended by the
manufacturers. RNA of adult pancreas was extracted as
previously reported (Serre-Beinier et al. 2000; Carvalho
et al. 2010). Briefly, samples were exposed to 4 M guani-
dine isothiocyanate in the presence of 2 M b-mercap-
toethanol and 2.5 mM Tris-HCl, layered on a 228 mM
CsCl/0.1 M EDTA cushion (pH 7.4), and centrifuged at
35,000 rpm for 20 h at 20 C. Pelleted RNA was resus-
pended in 10 mM Tris-HCl containing 5 mM EDTA and
0.1 % SDS. Samples were extracted three times with
phenol–chloroform–isoamyl alcohol, and precipitated in
ethanol. The dried pellets were resuspended in DEPC-H2O
and stored at -80 C. Total RNA from Min6, INS1-E, and
HeLa cells was extracted using Trizol (Invitrogen), as
recommended by the manufacturer. The RNA quality was
controlled using a laser Agilent 2100 bioanalyser. A total
of 1 lg (standard PCR) or 750 ng (quantitative PCR) total
RNA were reverse-transcribed using 200 U Reverse
transcriptase Superscript II (Invitrogen), 10 ng/ll random
hexamer primers (Promega) and 500 lM each dNTP mix
(Invitrogen). The mixture was heated to 65 C for 5 min
and quickly chilled on ice. First strand buffer (59),
10 mM dithiothreitol and 200 U Superscript II Reverse
transcriptase were then added (all reagents purchased from
Invitrogen). The samples were heated at 25 C for 10 min,
at 42 C for 50 min and at 70 C for a 15 min inactivation.
0.5 U RNase H (Roche) was then added for 20 min at
37 C.
For real-time PCR, we used a 1:10 (cell lines)–1:16
(tissues) dilution of the cDNA in a mix containing 29
QuantiTect SYBR Green PCR Master Mix (19; Qiagen)
and 300 nM each primer. The amplification protocol con-
sisted of a 10-min initial activation of the Taq polymerase
at 95 C, 40 cycles of denaturation at 95 C for 15 s, and
annealing at 65 C for 1 min. The following primers were
used: for Cx36, 50-GAC CAT CTT GGA GAG GCT GC-30
(F) and 50-ACC ACC ACA GTC AAC AGG ATC C-30
(R); for insulin2, 50-GCA GGA AGC CTA TCT TCC
AGG-30 (F) and 50-GGA CTC CCA GAG GAA GAG
CAG-30 (R); for Beta2/NeuroD1, 50-ACG CAG AAG GCA
AGG TGT C-30 (F) and 50-CCG CTC TCG CTG TAT
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GAT TT-30 (R); for Neurogenin3, 50-AGA ACT AGG
ATG GCG CCT CA-30 (F) and 50-GTG GCT AGG TGG
GGT GGA A-30 (R); for PDX1, 50-AAG AGC CCA ACC
GCG TC-30 (F) and 50-GTG TAA GCA CCT CCT GCC
CA-30 (R); for Cx32, 50-AGT GCC AGG GAG GTG TGA
AT-30 (F) and 50-ACA GCC ATA CTC GGC CAA T-30
(R); for connexin43 (Cx43), 50-ACT TTC ATT AAG TGA
AAG AGA GGT GCC-30 (F) and 50-GCC GTC GAG TAG
GCT TGG AG-30 (R); for RSP9, 50-GAC CAG GAG CTA
AAG TTG ATT GGA-30 (F) and 50-TCT TGG CCA GGG
TAA ACT TGA-30 (R); for HPRT, 50-GCT CGA GAT
GTC ATG AAG GAG AT-30 (F) and 50-AAG AAC TTA
TAG CCC CCC TTG A-30 (R). A melting curve was run at
the end of the 40 cycles to test for the presence of a unique
PCR reaction product, using the following protocol: 95 C
for 15 s, 60 C for 1 min and 95 C for 15 s. The PCR was
performed using the 7900HT PCR system (Applied Bio-
system). mRNA levels were normalized to those of the two
ubiquitous genes HPRT and RPS9. The stable expression of
these control genes in our samples was assessed using the
Genorm software.
Bioinformatics
The sequences of mouse, rat and human Cx36 genes were
compared using the multi-LAGAN function of the LAGAN
Alignment Toolkit Web site (http://lagan.stanford.edu/
lagan_web/ index.shtml). Conservation of response ele-
ments for Beta2/NeuroD1 was assessed using the Genom-
atix software (http://www.genomatix.de).
Cloning and Constructs
A -4,946/?485 fragment of Gjd2 (the transcription start
site being referred to as ?1) was isolated from the mouse
genomic library RP23-230H3 (Invitrogen), and cloned into
a pGL3b luciferase reporter vector (Promega). A -2,010/
-12 fragment was cloned in plasmid pCR4 (Invitrogen),
and used as source of the promoter region. To this end, a
SnabI/XhoI fragment (-1,524/?474) of pCR4 was ampli-
fied by PCR using the Platinum Pfx DNA Polymerase
(Invitrogen) and primers 50-CTA TAC GTA GAA TCA
CCG TCC CAT CTG TC-30 (F) and 50- CCG CTC GAG
GGA GGC AGC AGA CAA AGA CT-30 (R). The PCR
product was first subcloned in TOPO vector pCR2.1
(Invitrogen), before being excised with SacI and XbaI, and
inserted by ligation (T4 DNA ligase, Promega) into the
reporter vector pGL3b (Promega), upstream of a cDNA
coding for luciferase. Using the -1,524/?474 fragment as
substrate, and primers 50-AGA GTG CGG GAG TCC
ATC-30 (F) and 50-CCG CTC GAG GGA GGC AGC AGA
CAA AGA CT-30 (R), we then generated a ?192/?474
fragment, which was also subcloned in TOPO vector pCR2.1
(Invitrogen), excised with KpnI and XhoI, and inserted by
ligation (T4 DNA ligase, Promega) into the reporter vector
pGL3b (Promega), upstream of a cDNA coding for luciferase.
Expression vectors for Beta2/NeuroD1 (pCMV-BETA2), its
E47 coactivator (pCR3.1-E47) and the RIPE3 sequence
(pINSCAT448) were generously provided by Dr. H. Suh-Kim
(Kyonggi University, South Korea).
The mutated constructs 2Kb-E1m, 2Kb-E2m, and 2Kb-
E3m were generated using as substrate the -2,010/-12
promoter construct, and the QuikChange Multi Site
Directed Mutagenesis Kit (Stratagene), following the
instructions of the manufacturer. The primers used for each
construct were: for 2 Kb-E1 m, 50-CGC GGG AGC GCT
GGG TGC CCG CTC CAG TGA-30 (F) and 50 TCA CTG
GAG CGG GCA CCC AGC GCT CCC GCG-30 (R); for
2 Kb-E2 m, 50-GCA GGA GCT CGG CTG CCT GCA
CGC TGC C-30 (F) and 50-GGC AGC GTG CAG GCA
GCC GAG CTC CTG C-30 (R); for 2 Kb-E3 m, 50-AGA
CTG CGG GAG TCT GTC TGA CCC CCG G- 30 (F) and
50-CCG GGG GTC AGA CAG ACT CCC GCA GTC T-30
(R).
Cell Culture
MIN6 and HeLa cells were grown at 37 C, under 5 %
CO2, in Dulbecco’s modified Eagle’s medium (DMEM),
containing 110 U/ml penicillin, 110 lg/ml streptomycin,
and either 5 mM glucose plus 10 % heat-inactivated fetal
calf serum (HeLa cells) or 25 mM glucose plus 15 % heat-
inactivated FCS and 70 lM b-mercaptoethanol (MIN6
cells). INS-1E cells were grown at 37 C, under 5 % CO2,
in RPMI-1640 medium containing L-glutamine, 10 mM
Hepes, 5 % heat-inactivated fetal calf serum, 100 mM
Na-Pyruvate, 5 mM b-mercapto-ethanol, 110 U/ml peni-
cillin, and 110 lg/ml streptomycin
Transfection
Aliquots of 105 Min6, 105 INS1-E cells or 8 9 104 HeLa
cells were plated per well in 12-well plates. The next day,
cells were transfected using the Polyfect reagent (Qiagen),
as per the manufacturer instructions. Each of the reporter
pGL3b plasmids (1 lg) coding for a different Cx36 pro-
moter fragment, was individually transfected with or
without the plasmid pCMV-BETA2 (1 lg) coding for
Beta2/NeuroD1, and plasmid pCR3.1-E47 (140 ng) coding
for the E47 cofactor. In all experiments, 0.1 lg vector
pRL-TK (Promega) coding for Renilla luciferase was
cotransfected with these plasmids, to allow for a normali-
zation of the firefly luciferase activity induced by the
promoter reporter constructs. In each experiment, the total
DNA amount was adjusted to the same level using an
empty pCDNA.3 plasmid (Invitrogen).
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Luciferase Assay
Two days after transfection, cells were lysed in PLB, and
the activities of firefly (induced by the various pGL3b
vectors) and Renilla luciferase (induced by the pRL-TK
vector), were monitored using the Dual-luciferase reporter
assay kit (Promega), as per the manufacturer instructions.
To compare the basal activity of the various Gjd2 frag-
ments in the different cell lines, results are presented as
mean ? SEM luciferase activity, normalized to that of the
Renilla reporter. To compare the Beta2/NeuroD1 regula-
tion of the Gjd2 fragments in each cell line, we assessed
luciferase activity of cells cotransfected with plasmid
pCMV-BETA2 (coding for Beta2/NeuroD1), and plasmid
pCR3.1-E47 (coding for the E47 cofactor) or only with a
control empty vector. Data are shown as means ? SEM,
normalized to the luciferase activity of the respective
promoter fragment, which was transfected with the empty
vector.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP was performed as previously described (Masternak
et al. 2003). Briefly, crosslinked chromatin was prepared
by exposing 4 9 107 Min 6 cells to 1 % formaldehyde for
8 min at room temperature. Crosslinking was stopped by
the addition of 0.2 M glycine. The cells were then lysed in
TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8) con-
taining protease inhibitors and 0.5 % NP-40. Nuclei were
pelleted and lysed in TE containing 0.5 M NaCl, 1 %
Triton X-100 and 0.5 % sodium deoxycholate. Crosslinked
chromatin was resuspended in TE buffer supplemented
with 100 mM NaCl, sheared by sonication, and cleared by
two successive centrifugations, first at 4,000 rpm for
10 min and then at 13,000 rpm for 15 min. One aliquot of
10 lg sheared chromatin was saved for the input, while
another 10-lg aliquot was used for immunoprecipitation at
4 C overnight, using 2 lg rabbit polyclonal antibody
against NeuroD1 (Abgent AP2021b). The immune com-
plexes were captured at room temperature using protein
A-Sepharose beads (GE Healthcare Biosciences).The
immunoprecipitated chromatin fragments were eluted for
10 min at 65 C with 100 mM Tris-HCl containing 1 %
SDS (pH 8), digested for 2 h at 42 C with 150 lg/ml
Proteinase K, and incubated overnight at 65 C to reverse
the crosslinks. After extraction with phenol-chloroform and
chloroform, DNA was precipitated with isopropanol in the
presence of glycogen, washed in 75 % ethanol and resus-
pended in 50 ll TE buffer. The immunoprecipitated DNA
and the input chromatin DNA were analyzed by qPCR
using a SYBR-Green kit (Eurogentec) and the following
primers: for the Cx36 promoter, 50-CCTCAGACCGCAA
GATCG-30 (F) and 50-TGG GGG AAG CAA TCT ATG
TG-30 (R); for the insulin promoter, 50-TGT TGA CGT
CCA ATG AGC GCT TTC-30 (F) and 50-TA G GTC AGC
AGA TGG CCA GAG G-30 (R); for TG737, 50- GCC AAG
GCT ACA CAA GAC-30 (F) and 50-CAC CAG TGC TTC
CGA TTC-30 (R). A standard curve was generated with the
input chromatin, and binding of Beta2/NeuroD1 to the
Cx36 promoter was evaluated relative to that of the same
transcription factor to the insulin promoter, which was used
as positive control.
Statistical Analysis
Student’s t tests were used for statistical analysis
throughout the study. p values \0.05 were considered as
statistically significant.
Results
Gjd2 Transcription Starts during Early Pancreas
Development and Changes at Selected Time Points
To determine the temporal pattern of Cx36 expression, we
amplified RNA extracted from the pancreas of wild type
mice, age E11.5 onward. Real-time quantitative PCR
showed that the levels of Cx36 mRNA increased
(p \ 0.005) 12-fold between E11.5 and E15.5, and by a
further 1.6-fold (p \ 0.01) from E15.5 to P0 (Fig. 1a).
Thereafter, these levels apparently decreased (Fig. 1a) as a
result of the dilution of the endocrine transcripts in the total
pancreas extracts, as a result of the explosive, postnatal
expansion of the exocrine pancreas. This was confirmed by
the postnatal 3.5 increase in Cx32, a connexin isoform
expressed by the acinar cells of pancreas (Fig. 1a). The
mRNA levels of this connexin, as well as those of the Cx43
isoform, which is expressed in the nonendocrine and non-
acinar compartments of the pancreas, featured an expres-
sion pattern quite different from that of Cx36, during both
pre- and postnatal development of pancreas (Fig. 1a).
The first peak of Cx36 expression occurred at the pre-
natal time (E15.5) of the so called ‘‘secondary transition’’
(Pictet et al. 1972), during which b cells massively dif-
ferentiate, as revealed by increased transcription of the
insulin gene (Ins; Fig. 1b). The second peak of Cx36
expression (P0) also occurred at the time of increased
transcription of Ins, which reached adult levels within the
first 2 days of neonatal life (Fig. 1b). Quantitative PCR
further showed that the increase in Cx36 expression
between E13.5 and E15.5 coincided with that of Beta2/
NeuroD1, PDX1 (Fig. 1b) and Ngn3 (data not shown),
three transcription factors which are obligatory for proper
pancreas development and b-cell function (Itkin-Ansari
et al. 2005; Naya et al. 1995; Offield et al. 1996).
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Thereafter, the levels of these factors decreased up to the
adult age (Fig. 1b) as a result of the increasing growth of
the exocrine tissue. These experiments show that the
expression of Cx36 is initiated during early pancreas
development, and follows a temporal pattern which is
different from that of other connexins and which is initiated
at the time the expression of the insulin gene and of major
b-cell transcription factors surges.
To identify the cell types expressing Cx36, we immu-
nostained the pancreas of control C57Bl6 mice. No Cx36
was detected in the pancreas of E11.5, E13.5, and E15.5
mice, when few cells contained detectable levels of either
insulin (Fig. 2) or glucagon (data not shown). Later on,
Cx36 spots were found on insulin-containing (Fig. 2), but
were never observed in glucagon-containing cells (data not
shown). These experiments show that Cx36 is expressed
during the early development of the mouse pancreas, and
later becomes a specific attribute of b cells.
A Fragment of the Gjd2 Promoter Ensures the Specific
Expression of Cx36 in Insulin-producing Cells
To unravel the mechanism controlling the expression of
Cx36, we generated luciferase reporter plasmids coding for
fragments of the Gjd2 promoter, and transiently transfected
lines of the insulin-producing Min6 and INS1-E cells, as
well as the nonendocrine line of HeLa cells. When com-
pared to the void vector, the 282-bp promoter fragment
induced a similar increase (p \ 0.001) in luciferase activity
in the three cell types (Fig. 3a). The 2- and 5-kbp frag-
ments also significantly increased (p \ 0.001) luciferase
activity over that seen in cells transfected with the void
vector (Fig. 3a). However, this effect was significantly
larger (p \ 0.01) in the two insulin-producing lines than in
HeLa cells (Fig. 3a). The results indicate that the 2-kbp
fragment of the Gjd2 promoter is sufficient to ensure a
specific expression of Cx36 in insulin-producing cells, and
that the region comprised between -2,010 and -294 bp
contains elements that regulate its expression level.
In silico analysis identified in this region three E boxes
with a CANNTG sequence characteristic of cis-elements
binding bHLH factors (Sommer et al. 1996; Robinson et al.
2000), which were referred to as E1, E2 and E3, at position
-280, -332, and -445, respectively (Fig. 3b). Compari-
son of the sequences of these E boxes of mouse, rat and
human Gjd2, showed a highly conservation of the canonic
CANNTG sequence, especially in E1 and E3 (Fig. 3c).
A Fragment of the Gjd2 Promoter Binds Beta2/
NeuroD1, Which Transactivates Cx36 Expression
Beta2/NeuroD1 is a bHLH transcription factor central to
the development and differentiation of both b cells (Her-
rera 2000; Itkin-Ansari et al. 2005; Naya et al. 1995a;
Offield et al. 1996; Sommer et al. 1996; Robinson et al.
2000; Naya et al. 1994, 1995) and neurons (Masternak
et al. 2003; Lee 1995, 1997; Liu et al. 2000; Poulin et al.
1997), which binds to E boxes to regulate the expression of
the insulin gene (Ins; Itkin-Ansari et al. 2005; Naya et al.
1995). To test whether Beta2/NeuroD1 also binds to Gjd2
promoter, we run chromatin immunoprecipitation assays
on Min6 cells. We first validated the protocol by assessing
the immunoprecipitated chromatin using primers for the
promoter of Ins (Fig. 4a) which, thereafter, was used as
normalization standard. Relative to this standard, the
binding of Beta2/NeuroD1 to the region of the Gjd2
Fig. 1 Gjd2 transcription is detected in early pancreas development,
and changes at selected time points. a Real-time PCR showed that the
levels of the Cx36 mRNA (solid columns) increased sharply between
E13.5 and E15.5, and at birth (P0), in contrast to those of both Cx43
(grey bars) and Cx32 transcript (open bars). b Prenatal and neonatal
increase in the levels of the insulin mRNA (cross-hatched bars) was
coincident with that of Cx36 mRNA (solid bars in a). The increased
transcription of Cx36 between E13.5 and E15.5 (solid bars in a) was
also coincident with that of Beta2/NeuroD1 (diagonally hatched bars)
and PDX1 (vertically hatched bars). Bars represent the mean ? SEM
fold change in mRNA level, relative to the level evaluated at E11.5;
n = 4 for E13.5–E17.5; n = 5 for E11.5 and P times
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promoter that contained E boxes represented 43 ± 15 %
(Fig. 4a). This binding was significantly higher (p \ 0.05)
than the nonspecific binding of the transcription factor to
either a downstream region of the Gjd2 promoter or to a
region of the promoter of the unrelated TG737, which
served as negative controls (Fig. 4a). The results show that
Beta2/NeuroD1 specifically binds to the region of the Gjd2
promoter containing the three E boxes.
To investigate whether this binding modulated the
expression of Cx36, we cotransfected Beta2/NeuroD1,
together with the ubiquitous cofactor E47 which is
required for its activity (Qiu et al. 2002; Mirasierra and
Vallejo 2006; Kim et al. 2002; Docherty et al. 2005),
and one of the 5.4-kbp, 2-kbp, or 282-bp Gjd2 promoter
constructs (Fig. 4a) in Min6, INS1-E and HeLa cell lines.
Although the former two insulin-producing cell types
natively express Beta2/NeuroD1, the latter does not
(Fig. 4b) and thus provided for a negative control. The
parallel transfection of the RIPE3-luc construct, which
contained three multimerized copies of the E box of the
rat Ins promoter upstream of a luciferase reporter
sequence (Kim et al. 2002; Henderson and Stein 1994),
provided for a positive control. Relative to the basal
luciferase activity observed in cells that had not been
transfected with Beta2/NeuroD1 and E47, cells transfec-
ted for these factors plus the void pGL3b vector did not
show a change in luciferase activity (Fig. 4c). In con-
trast, transfection of the RIPE3 construct resulted in a
significant increase (p \ 0.01) in luciferase activity in the
three cell types (Fig. 4c). Under these conditions, which
validated the experimental protocol, the 282-bp fragment
of Gjd2, which contained the E3 box, did not signifi-
cantly modify the luciferase activity (Fig. 4c). In con-
trast, this activity was significantly increased (p \ 0.005)
over basal values after transfection of either the 2-kbp or
the 5.4-kbp fragments of Gjd2, which contained the E1,
E2 and E3 boxes (Fig. 4c). These results show that
Beta2/NeuroD1 transactivates the promoter of Gjd2 via
cis-elements of the 5.4-kbp and the 2-kbp fragments,
possibly E1 and E2.
To test the role of these sequences, each of the three E
boxes was mutated by scrambling the consensus core
sequence CANNTG in the 2-kbp fragment of the Gjd2
promoter, which was chosen because it provided for the
largest effect of Beta2/NeuroD1 (Fig. 4c). Thus, four
mutated versions of the 2-kbp promoter were constructed,
three carrying a single mutated E box and one carrying a
combined mutation of the three E boxes (Fig. 4d). The
mutated constructs were then tested in INS1-E and HeLa
cells after cotransfection with Beta2/NeuroD1 and E47.
Compared to the luciferase activity of the wild-type 2-kbp
construct, the activity observed after mutation of E1 was
significantly reduced (p \ 0.05), whereas that observed
after a mutation of either E2 or E3 had a minimal effect
(Fig. 4d). The effect of the E1 mutation was larger
(p \ 0.005) in the presence of a concurrent mutation of E2
and E3 (Fig. 4d). The results indicate that Beta2/NeuroD1
transactivates Gjd2 via the native E boxes of its promoter.
Fig. 2 The Cx36 protein is detected in b cells during late pancreas
development. The same area of a control mouse pancreas is shown
after staining of cell nuclei (DAPI, blue), Cx36 (green), and insulin
(red). Cx36 was immunodetected from E17.5 onward and showed a
punctate distribution only in insulin-containing b cells (red). Bars
15 lm
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Discussion
We have investigated the pattern of Cx36 expression dur-
ing pancreas development and the differentiation of pan-
creatic b cells. Our data confirm that Gjd2 is transcribed
during the early prenatal development of pancreas (Ber-
thoud et al. 2004; Pe´rez-Armendariz et al. 2012), before the
first wave of b cells can be detected (Theis et al. 2004;
Herrera 2000; Berthoud et al. 2004; Pe´rez-Armendariz
et al. 2012). Using antibodies, we have further shown that
Cx36 becomes detectable at later stages of the prenatal
pancreas development, but only in cells containing im-
munodetectable insulin. Cx36 largely increases in these
cells during the neonatal period, when b cells acquire their
major differentiation characteristic, i.e. the ability to rec-
ognize circulating glucose as a stimulus for insulin secre-
tion (Gulisano et al. 2000; Herrera 2000; Carvalho et al.
2010, 2012). This evolution is consistent with the previous
findings that Cx36 is required for the proper functioning of
differentiated islets (Ravier et al. 2005; Speier et al. 2007;
Klee et al. 2011), and provides the first clue that this
requirement actually precedes the functional maturation of
these microorgans. Strikingly, immunolabeling showed no
association between Cx36 and the glucagon-containing
a-cells, extending previous biochemical, immunological
and functional observations (Serre-Beinier et al. 2000;
Theis et al. 2004; Bosco et al. 2011; Kim and MacDonald
2002), which indicated that, throughout rodent life, Cx36
expression and signalling are solely restricted to the b-cell
lineage.
The initial surge of Gjd2 occurred at the time (E13.5–
E15.5), the first wave of b cells is induced (Herrera 2000;
Kim and MacDonald 2002; Habener et al. 2005), as evi-
denced by the concomitant induction of the insulin gene.
Fig. 3 A promoter fragment
ensures the specific expression
of Gjd2 in insulin-producing
cells. a Three fragments of the
Gjd2 promoter were transiently
transfected, using a luciferase
reporter plasmid. The 282-bp
fragment increased luciferase
activity over that provided by an
empty pGL3b vector in MIN6
(solid bars), INS1E (hatched
bars), and HeLa cells (open
bars). The 2-kbp and 5-kbp
constructs induced a smaller
increase, which was restricted to
the insulin-producing MIN6 and
INS1E cells. Values are
mean ? SEM of 3 experiments
and are shown after
normalization to the luciferase
activity observed in cells
transfected with pRL-TK. b The
partial sequence of the Gjd2
promoter shows the position
(relative to that of the
translation start site, which is
referred to as ?1) of the 3 E
boxes (red). The previously
identified NRSE (Martin et al.
2003) is shown in blue.
c Alignment of the mouse, rat,
and human Cx36 promoters
shows the conservation of the
consensus CANNTG sequence
of the 3 E boxes
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This coincidence was not observed for either Cx32 or
Cx43, showing that the pattern of Cx36 expression is
specifically controlled at key moments of b-cell develop-
ment. In turn, this timing suggests that Cx36 may be
implicated in this development and/or be regulated by the
very same transcription factors that determine pancreas
differentiation. Quantitative PCR indeed documented that
the prenatal Gjd2 expression increases at the same time of
the expression surge of the major transcription factors
which contribute to the specification and differentiation of
pancreatic b cells (Herrera 2000; Kim and MacDonald
2002; Habener et al. 2005). Previous studies have shown
that the RE-1 silencing transcription factor (REST) pre-
vents the expression of Gjd2 in non-insulin-producing and
nonneuronal cells (Martin et al. 2003; Hohl and Thiel
2005). However, no transcription factor was so far identi-
fied as a transactivator of the expression of this gene. Our
data show that a 2-kbp region of mouse Gjd2 contains cis-
regulatory elements that are sufficient to determine the
expression of Cx36 in insulin-producing cells. We further
document that this region allows for the binding of the
transcription factor Beta2/NeuroD1 to a specific E box (E1)
of the Gjd2 promoter. In the presence of its coactivator
E47, Beta2/NeuroD1 transfection resulted in the transac-
tivation of this promoter, which was potentiated by the two
close-by E2 and E3 boxes. The extent of the transactivation
of the 2-kbp and 5.4-kbp fragments induced by Beta2/
NeuroD1 was lower in the insulin-producing cells than
in the unrelated HeLa cells, suggesting that endogenous
Beta2/NeuroD1 resulted in a higher basal transcriptional
activity of Gjd2 in the former cell type. Consistent with this
hypothesis, mutation of E1 resulted in loss of the Gjd2
transactivation dependent on the expression of transfected
Beta2/NeuroD1, but not of the basal activity of the Cx36
promoter in INS-1E cells (data not shown). This finding
implies that multiple factors converge to regulate the
expression of the Cx36 gene in insulin-producing cells, as
is the case for the insulin gene Ins, which is selectively
regulated by the combinatorial effect of Beta2/NeuroD1,
PDX1, and MafA transcription factors (Aramata et al.
2005). The Gjd2 promoter contains putative binding sites
for PDX1 (data not shown). However, these sites are
not highly conserved, in spite of the consistent b cells
expression of Cx36 in all species so far investigated
Fig. 4 Beta2/NeuroD1 binds to E boxes and transactivates the Gjd2
promoter. a DNA of Min6 cells was immunoprecipitated using
antibodies to Beta2/NeuroD1, then amplified by qPCR. Beta2/
NeuroD1 bound to the region of the Gjd2 promoter containing the
E boxes more than to a Gjd2 region devoid of E boxes and to the
unrelated Tg737 promoter. Data are mean ? SEM from 3 indepen-
dent experiments and are expressed relative to the binding of Beta2/
NeuroD1 to the Ins promoter, which served as positive control. b RT-
PCR showed the native expression of Beta2/NeuroD1 in MIN6 and
INS1E cells, but not in HeLa cells. Brain served as positive control.
c After transient cotransfection with Beta2/NeuroD1 and E47, the
282-bp fragment of the Gjd2 promoter did not increase luciferase
activity of Min6 (solid bars), INS1-E (horizontally hatched bars), and
HeLa cells (open bars), over the basal level observed in nontrans-
fected cells (obliquely hatched bars), whereas the 2-kbp and the 5.4-
kbp fragments did. The RIPE3 and the void pGL3B plasmids served
as positive and negative controls, respectively. Values are mean ?
SEM of 3 experiments and are expressed relative to the luciferase
activity observed in cells transfected with pRL-TK. d After transient
cotransfection with Beta2/NeuroD1 and E47, the 2-kbp fragment of
Gjd2 increased the luciferase activity of INS1-E cells (horizontally
hatched bars) and HeLa cells (open bars) over the basal level
observed in nontransfected cells (obliquely hatched bars). This effect
was decreased after mutation of E1, blocked after the combined
mutation of the 3 E boxes, but unaffected after mutation of either E2
or E3. Values are mean ? SEM luciferase activity of 3 experiments,
relative to the basal luciferase activity evaluated in the absence of
exogenous Beta2/NeuroD1 (obliquely hatched bars)
b
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(Serre-Beinier et al. 2000; Theis et al. 2004; Pe´rez-
Armendariz et al. 2012; Le Gurun et al. 2003), raising con-
cerns that they may be dispensable for Cx36 expression.
An implication of these results is that some of the effects
attributable to Beta2/NeuroD1 signaling, which has been
shown to be essential for the terminal differentiation and
survival of the b cells (Habener et al. 2005; Naya et al.
1995a), may be mediated by Cx36. The validation of this
tentative conclusion awaits further studies on the molecular
mechanism linking the timely related changes in the
expression of these two proteins. Strikingly, mice lacking
Beta2/NeuroD1 die around birth, with severe diabetes,
ketoacidosis (Naya et al. 1997), and neuronal alterations
(Miyata et al. 1999). Future studies should therefore eval-
uate whether altered Cx36 expression may be implicated in
these defects. The previous reports that mice lacking this
connexin show altered b-cell function (Carvalho et al.
2010; Ravier et al. 2005; Speier et al. 2007; Klee et al.
2011; Wellershaus et al. 2008) is consistent with this view.
The observation that these animals do not feature major
alterations in the development of islets and b-cell differ-
entiation (Ravier et al. 2005; Klee et al. 2011; Wellershaus
et al. 2008; Degen et al. 2004) only indicates that Cx36 is
but one of the many actors that participate in the complex
regulation of islet development and b-cell function (Mac-
Donald 2007; MacDonald and Rorsman 2007). Thus, loss
of Cx36 signaling may be compensated by other mecha-
nisms, as documented in neurons (Cummings et al. 2008).
The key importance of Beta2/NeuroD1 in pancreas devel-
opment and function is further stressed by the observations
that mutations inactivating the Beta2/NeuroD1 gene cause
one of the rare monogenic forms of diabetes, referred to as
MODY6 (Malecki et al. 1999), and that several variants of
this gene confer susceptibility to the much more frequent
type I and type II forms of diabetes (Iwata et al. 1999;
Malecki et al. 2003; Yamada et al. 2001). The mechanism
linking the genetic mutations to the various forms of the
disease remains unknown. However, together with the
reports that mice lacking Cx36 develop structurally normal
islets which cannot sustain normal insulin secretion (Ravier
et al. 2005; Speier et al. 2007; Klee et al. 2011; Wellers-
haus et al. 2008; Head et al. 2012; Meda 2012), the clinical
data implicate that the predominant effect of the regulation
of Cx36 expression by Beta2/NeuroD1 is likely on the
function, rather than on the mass of the insulin-producing b
cells (Martin et al. 2003; Bosco et al. 2011; Head et al.
2012; Meda 2012).
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